(Reuters) – Drug developer Vaxart Inc on Tuesday said it has given a dose of its oral COVID-19 vaccine candidate to a participant in an early-stage study.
The trial will evaluate two doses of the vaccine candidate, VXA-CoV2-1, in up to 48 healthy volunteers aged between 18 and 54 years old.
(Reporting by Manojna Maddipatla in Bengaluru, Editing by Sherry Jacob-Phillips)
